KA-3006 / KYinno - LARVOL DELTA

The bispecific antibody KA-3006 against both EGFR and MET surpasses amivantamab in efficacy (AACR 2024) - "Finally, we assessed the developability of this BsAb with different treatments such as high concentration, low pH, repeated freezing and thawing, and high temperature, and KA-3006 showed neither aggregation nor degradation. In conclusion, the BsAb KA-3006, developed with our common light chain antibody discovery platform, is a promising pre-clinical candidate drug for the treatment of various solid cancers with overactivated EGFR and MET signaling, and it holds potential for developing ADCs targeting both EGFR and MET."

Clinical • Oncology • Solid Tumor • EGFR